|1.||Walker, Brian R: 25 articles (01/2013 - 07/2002)|
|2.||Stewart, Paul M: 25 articles (12/2010 - 01/2002)|
|3.||Seckl, Jonathan R: 20 articles (03/2011 - 07/2003)|
|4.||Tomlinson, Jeremy W: 13 articles (12/2010 - 04/2002)|
|5.||Stewart, P M: 12 articles (06/2010 - 01/2001)|
|6.||Andrew, Ruth: 10 articles (01/2013 - 07/2002)|
|7.||Walker, B R: 10 articles (09/2007 - 01/2000)|
|8.||Morton, Nicholas M: 9 articles (01/2010 - 07/2003)|
|9.||Chapman, Karen E: 8 articles (01/2013 - 06/2006)|
|10.||Olsson, Tommy: 8 articles (07/2010 - 07/2002)|
06/01/2010 - "Animal studies indicate a role for 11beta-hydroxysteroid dehydrogenase type 1 (HSD11B1) in the development of obesity. "
12/01/2009 - "Recent studies in humans and animal models of obesity have shown increased adipose tissue activity of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which amplifies local tissue glucocorticoid concentrations. "
05/01/2007 - "This study aimed to assess in a rat model of diet-induced obesity the effects of pharmacological 11beta-HSD1 inhibition on the morphology and expression of key genes of lipid metabolism in intraabdominal adipose depots. "
01/01/2004 - "The aim of this study was to determine whether up-regulation of human adipose 11beta-HSD1 in obesity can also be found at the gene expression level. "
02/01/2001 - "The main results of our study are the exclusion of a common association of 11beta-HSD1 mutations to obesity and the identification of two novel allelic variants for the gene 11beta-HSD1 in the Italian population, not previously described in any database."
|2.||Body Weight (Weight, Body)
06/01/2003 - "We observed an inverse relationship between hepatic 11beta-HSD1 expression and body weight in ob/ob mice and lean littermates. "
04/01/2008 - "The reduced body weight and improved metabolic control in mice with high fat diet-induced obesity upon daily CBX administration highlights the potential value of selective 11beta-HSD1 inhibition as a new route for the treatment of type 2 diabetes and obesity."
09/01/2006 - "11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue and prospective changes in body weight and insulin resistance."
05/01/2007 - "Rats fed a high-sucrose, high-fat diet were treated or not with a specific 11beta-HSD1 inhibitor (compound A, 3 mg/kg.d) for 3 wk. Compound A did not alter food intake or body weight gain but specifically reduced mesenteric adipose weight (-18%) and adipocyte size, without significantly affecting those of epididymal or retroperitoneal depots. "
06/01/2003 - "In addition, leptin treatment of STZ-treated ob/ob mice caused marked increases in hepatic 11beta-HSD1 levels associated with decreased body weight and a significant reduction in hyperglycemia due to pancreatic beta-cell damage. "
|3.||Cardiovascular Diseases (Cardiovascular Disease)
07/05/2010 - "Inhibition of tissue-specific glucocorticoid action by regulating 11beta-HSD1 constitutes a promising treatment for metabolic and cardiovascular diseases. "
03/25/2009 - "Therefore, inhibition of tissue-specific glucocorticoid action by regulating 11beta-HSD1 constitutes a promising treatment for metabolic and cardiovascular diseases. "
09/01/2006 - "Inhibition of tissue-specific glucocorticoid activation by 11beta-HSD1 constitutes a promising target in the treatment of metabolic and cardiovascular diseases. "
08/01/2007 - "As 11beta-HSD1 expression in lean women was found to be significantly lower than in lean males, the up-regulation associated with obesity may be relatively more devastating in women than in men, and may help explain the higher relative risk of cardiovascular disease in women suffering from the metabolic syndrome."
09/01/2007 - "Selective 11beta-HSD1 inhibitors in rodents cause weight loss, improve insulin sensitivity and delay progression of cardiovascular disease. "
08/15/2005 - "11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice."
07/01/2009 - "This study reinforces the potential use of 11beta-HSD1 inhibitors in patients with the metabolic syndrome without negatively impacting atherosclerosis."
07/01/2009 - "Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis."
03/01/2009 - "Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 have been shown recently to ameliorate cardiovascular risk factors and inhibit the development of atherosclerosis. "
08/15/2005 - "Most importantly, inhibition of 11beta-HSD1 slowed plaque progression in a murine model of atherosclerosis, the key clinical sequela of metabolic syndrome. "
|5.||Hypertension (High Blood Pressure)
09/01/1997 - "In the present study we measured the activity of hepatic and kidney 11beta-HSD1 in Dahl-S and R rats before and after the development of hypertension. "
12/12/2008 - "Renal medullary 11 beta-hydroxysteroid dehydrogenase type 1 in Dahl salt-sensitive hypertension."
06/01/2008 - "[Possible pathogenetic role of 11 beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) gene polymorphisms in arterial hypertension]."
07/01/2003 - "Taken together, our findings suggest that overexpression of 11beta-HSD1 in fat is sufficient to cause salt-sensitive hypertension mediated by an activated RAS. "
11/01/2004 - "11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) is a candidate gene for hypertension, diabetes, and obesity through altered glucocorticoid production. "
|6.||11-beta-Hydroxysteroid Dehydrogenase Type 2 (11 beta-Hydroxysteroid Dehydrogenase Type 2)
|1.||Carbohydrate-Restricted Diet (Low Carbohydrate Diet)
|2.||Highly Active Antiretroviral Therapy (HAART)